Celebrating 40 years, Dr Reddy s Laboratories stands out in the Indian pharma industry for its focus on governance and innovation. Founded in 1984 by scientist Dr Anji Reddy, the company has had a history of bold moves like early public listing, investing in drug discovery or hiring an expat CEO. Little wonder that the company has ended up being a CEO factory for the Indian pharma industry. The company has also been open about its mistakes and challenges like a large acquisition that fell short of expectations. Join hosts Kiran Somvanshi and Arijit Barman in a candid conversation with G.V. Prasad, Co-Chairman and Managing Director on Dr. Reddy s journey and future on The Morning Brief podcast!
The market will get a direction once we get a range breakout. However, three stocks have formed a good setup on the technical charts and can give returns in the short term.
The drugmaker is expected to report a 1.1% YoY drop in consolidated net profit to Rs 1,247 crore, according to the average of estimates given by seven brokerages. The company is scheduled to release its quarterly earnings on Tuesday.
A large part of the impact on India depends on whether Iran, a major Hamas supporter, is drawn into the war. "That can disrupt oil supplies causing a spike in crude, which can trigger a risk-off in the market," said Dr. V K Vijayakumar of Geojit Financial Services.
This looks at the total remuneration of senior employees in the pharma space. Remuneration here is the director s salary inclusive of benefits like ESOPs